Developing a UK-Korean partnership to inform global tuberculosis control: treatment of neglected patterns of drug resistant disease

Project Details


Tuberculosis (TB) is a chronic infectious disease with a substantial global burden. Isoniazid and rifampicin are critical for the treatment of both TB disease and clinically latent TB infections. Resistance to these drugs, either combined (multidrug resistant TB; MDR TB) or individually (non-MDR isoniazid resistance, non-MDR rifampicin resistance), is common; ~10% of patients internationally have non-MDR isoniazid resistant TB and ~1% non-MDR rifampicin resistant TB. Treatment recommendations for these drug resistance profiles are inconsistent globally, with substantial evidence gaps. High quality observational and randomised controlled trial data are required to provide a firm evidence base for successful patient therapy.

The Republic of Korea has a high burden of TB, with an incidence rate of 80/100,000 in 2015. It is well-resourced in terms of medical infrastructure and is an excellent setting for planning such studies.

This grant, held jointly with The Catholic University of Korea/Incheon St. Mary’s Hospital, Republic of Korea, undertook the groundwork for future studies to fill the evidence gap surrounding non-MDR drug resistant TB.
Effective start/end date22/05/1721/05/18